These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 29471895)

  • 21. HDAC6 inhibition enhances 17-AAG--mediated abrogation of hsp90 chaperone function in human leukemia cells.
    Rao R; Fiskus W; Yang Y; Lee P; Joshi R; Fernandez P; Mandawat A; Atadja P; Bradner JE; Bhalla K
    Blood; 2008 Sep; 112(5):1886-93. PubMed ID: 18591380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective apoptosis of tandemly duplicated FLT3-transformed leukemia cells by Hsp90 inhibitors.
    Minami Y; Kiyoi H; Yamamoto Y; Yamamoto K; Ueda R; Saito H; Naoe T
    Leukemia; 2002 Aug; 16(8):1535-40. PubMed ID: 12145695
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ETV6: a versatile player in leukemogenesis.
    Bohlander SK
    Semin Cancer Biol; 2005 Jun; 15(3):162-74. PubMed ID: 15826831
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of heat shock protein 90 function by 17-allylamino-17-demethoxy-geldanamycin in Hodgkin's lymphoma cells down-regulates Akt kinase, dephosphorylates extracellular signal-regulated kinase, and induces cell cycle arrest and cell death.
    Georgakis GV; Li Y; Rassidakis GZ; Martinez-Valdez H; Medeiros LJ; Younes A
    Clin Cancer Res; 2006 Jan; 12(2):584-90. PubMed ID: 16428504
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Hsp90 inhibitor 17-allylamide-17-demethoxygeldanamycin induces apoptosis and differentiation of Kasumi-1 harboring the Asn822Lys KIT mutation and down-regulates KIT protein level.
    Yu W; Rao Q; Wang M; Tian Z; Lin D; Liu X; Wang J
    Leuk Res; 2006 May; 30(5):575-82. PubMed ID: 16213582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The HSP90 inhibitor 17-AAG synergizes with doxorubicin and U0126 in anaplastic large cell lymphoma irrespective of ALK expression.
    Georgakis GV; Li Y; Rassidakis GZ; Medeiros LJ; Younes A
    Exp Hematol; 2006 Dec; 34(12):1670-9. PubMed ID: 17157164
    [TBL] [Abstract][Full Text] [Related]  

  • 27. FLT3 tyrosine kinase as a target molecule for selective antileukemia therapy.
    Naoe T; Kiyoe H; Yamamoto Y; Minami Y; Yamamoto K; Ueda R; Saito H
    Cancer Chemother Pharmacol; 2001 Aug; 48 Suppl 1():S27-30. PubMed ID: 11587362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Regulation of Ubiquitin-like with Plant Homeodomain and RING Finger Domain 1 (UHRF1) Protein Stability by Heat Shock Protein 90 Chaperone Machinery.
    Ding G; Chen P; Zhang H; Huang X; Zang Y; Li J; Li J; Wong J
    J Biol Chem; 2016 Sep; 291(38):20125-35. PubMed ID: 27489107
    [TBL] [Abstract][Full Text] [Related]  

  • 29. ETV6 gene aberrations in non-haematological malignancies: A review highlighting ETV6 associated fusion genes in solid tumors.
    Biswas A; Rajesh Y; Mitra P; Mandal M
    Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188389. PubMed ID: 32659251
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful allogeneic stem cell transplantation with long-term remission of ETV6/FLT3-positive myeloid/lymphoid neoplasm with eosinophilia.
    Chonabayashi K; Hishizawa M; Matsui M; Kondo T; Ohno T; Ishikawa T; Takaori-Kondo A
    Ann Hematol; 2014 Mar; 93(3):535-7. PubMed ID: 23873282
    [No Abstract]   [Full Text] [Related]  

  • 31. Identification of ANLN as ETV6 partner gene in recurrent t(7;12)(p15;p13): a possible role of deregulated ANLN expression in leukemogenesis.
    Campregher PV; Pereira WO; Lisboa B; Puga R; Helman R; Miyagi M; da Mata EH; Datoguia TS; Velloso ED; Bacal NS; Ross JS; Ali S; Miller V; Costa FF; Hamerschlak N; Santos FP
    Mol Cancer; 2015 Nov; 14():197. PubMed ID: 26584717
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of heat shock protein 90 impairs epidermal growth factor-mediated signaling in gastric cancer cells and reduces tumor growth and vascularization in vivo.
    Lang SA; Klein D; Moser C; Gaumann A; Glockzin G; Dahlke MH; Dietmaier W; Bolder U; Schlitt HJ; Geissler EK; Stoeltzing O
    Mol Cancer Ther; 2007 Mar; 6(3):1123-32. PubMed ID: 17363505
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin.
    da Rocha Dias S; Friedlos F; Light Y; Springer C; Workman P; Marais R
    Cancer Res; 2005 Dec; 65(23):10686-91. PubMed ID: 16322212
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MS-275, a novel histone deacetylase inhibitor with selectivity against HDAC1, induces degradation of FLT3 via inhibition of chaperone function of heat shock protein 90 in AML cells.
    Nishioka C; Ikezoe T; Yang J; Takeuchi S; Koeffler HP; Yokoyama A
    Leuk Res; 2008 Sep; 32(9):1382-92. PubMed ID: 18394702
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ETV6/RUNX1 transcript is a target of RNA-binding protein IGF2BP1 in t(12;21)(p13;q22)-positive acute lymphoblastic leukemia.
    Stoskus M; Vaitkeviciene G; Eidukaite A; Griskevicius L
    Blood Cells Mol Dis; 2016 Mar; 57():30-4. PubMed ID: 26852652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Drug-mediated targeted disruption of multiple protein activities through functional inhibition of the Hsp90 chaperone complex.
    Stravopodis DJ; Margaritis LH; Voutsinas GE
    Curr Med Chem; 2007; 14(29):3122-38. PubMed ID: 18220746
    [TBL] [Abstract][Full Text] [Related]  

  • 37. ETV6-NCOA2: a novel fusion gene in acute leukemia associated with coexpression of T-lymphoid and myeloid markers and frequent NOTCH1 mutations.
    Strehl S; Nebral K; König M; Harbott J; Strobl H; Ratei R; Struski S; Bielorai B; Lessard M; Zimmermann M; Haas OA; Izraeli S
    Clin Cancer Res; 2008 Feb; 14(4):977-83. PubMed ID: 18281529
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 17-Allylamino-17-demethoxygeldanamycin (17-AAG) is effective in down-regulating mutated, constitutively activated KIT protein in human mast cells.
    Fumo G; Akin C; Metcalfe DD; Neckers L
    Blood; 2004 Feb; 103(3):1078-84. PubMed ID: 14551138
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A constitutively active SPTBN1-FLT3 fusion in atypical chronic myeloid leukemia is sensitive to tyrosine kinase inhibitors and immunotherapy.
    Grand FH; Iqbal S; Zhang L; Russell NH; Chase A; Cross NC
    Exp Hematol; 2007 Nov; 35(11):1723-7. PubMed ID: 17764812
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ETV6/ARG oncoprotein confers autonomous cell growth by enhancing c-Myc expression via signal transducer and activator of transcription 5 activation in the acute promyelocytic leukemia cell line HT93A.
    Iriyama N; Hatta Y; Takei M
    Leuk Lymphoma; 2015; 56(8):2416-23. PubMed ID: 25373509
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.